Retatrutide is a single peptide molecule designed to activate three receptor systemsGIP, GLP-1, and glucagon
Forecasts predict that the global GLP-1 market will reach $5.56 billion USD by 2030 due to new drug launches and the rising prevalence of diabetes across high-income countries.* "The North American and European markets, while similar, have unique cultural nuances that will impact treatment adoption and engagement beyond healthcare," said Chlo Depiesse, Managing Director Havas Health Network
Both are prescribed for diabetes
This distinction is especially important when a drug is still investigational
I will not work another day for you
Instead, were seeing a surge of altered, compounded GLP-1 products being marketed aggressively to consumers